Oncology/Hematology Research Awards Program Eligibility Page

Applicants must meet the following requirements. Proposals not meeting the requirements listed below will be rejected.

Academic Eligibility

To be eligible:
  • Study must take place entirely in the US, all sites must be located in the US. Principle Investigator and sponsoring organization must be located in the United States
  • Applicant (PI) must have a medical degree (MD or equivalent), or an advanced nursing degree (RN with a MS/PhD)

Note: Current external review panel members are not eligible to apply, either as applicant or co-applicant. Serving as a mentor to the applicants is permitted.

Research Requirements

Investigators are expected to:
  • Design studies and generate data to address at least one of the research areas of interest
  • Provide a publication plan with an intention to present at a medical conference or publish in a peer-reviewed journal. All Publications must follow ICH guidelines.
  • Complete the study within 24-30 months from the time grant awarded

Criteria for Selection - Independent, External Review Committee

The ASPIRE applications will be reviewed by an independent, external review committee comprised of experts in the fields of oncology/hematology. Grants will be awarded based upon:

  • Scientific merit of the research proposal
  • Qualifications of the Applicant
  • Relevance of proposed research to the program's mission
  • Evidence of the Applicant's commitment to an academic research career
  • Evidence of a suitable research environment

Note: A preliminary review of submissions will be completed by Pfizer in order to ensure proposals are within the scope of research areas, and that there are no concerns with the proposed work from a patient safety or intellectual property perspective.

Other Funding

No other government, non-governmental, or industry-sponsored projects may cover the same work scope as the grant application to the ASPIRE Awards. However, an ASPIRE grant may be related to other funding from foundations or government agencies, as long as there is no direct overlap. It is the responsibility of the applicant to justify the novelty of the proposal and provide evidence that the application does not overlap with any current or pending fundings.

Once awarded, an ASPIRE grant cannot be amended upwards with additional funding support from Pfizer (via the standard IIR process or separate competitive grant program), nor can additional drug support above and beyond what is sufficient to complete the original study as reviewed and approved by the external review committee be provided. If supplemental funding is required, it must be secured from sources outside of Pfizer. Similarly, an ongoing Pfizer supported standard IIR cannot apply for supplemental funding via a Pfizer supported competitive grant program. ASPIRE awards cannot be provided to studies that are already in progress.

Questions

See the Frequently Asked Questions (FAQ) for help.

You may also e-mail questions to 2017ASPIREonc@pfizer.com


Updated 11/23/16